MSLN
Mesothelin
As of the edition of 20 October 2026, MSLN (mesothelin, UniProt Q13421) has 10 drugs tested at it and 10 companies on the list, 8 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13421
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- In more than one place
- Solved structures
- 12
- Disease areas
- Cancer; Lungs and airways; Hormones; Digestive system; Pregnancy and women's health; Urinary and reproductive; Skin and connective tissue; Blood and lymph
- Registered trials of its drugs
- 43
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 6 |
| Status not established | 2 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Anetumab ravtansine | Stopped | Phase 2 | none listed |
| LMB-100 | Stopped | Phase 2 | none listed |
| Amatuximab | Stopped | Phase 2 | none listed |
| RC88 | Status not established | Phase 2 | none listed |
| BMS-986148 | Stopped | Phase 2 | none listed |
| Ss1(dsfv)-pe38 | Stopped | Phase 1 | none listed |
| ABBV-428 | Went quiet | Phase 1 | none listed |
| JNJ-79032421 | Status not established | Phase 1 | none listed |
| RG-7600 | Went quiet | Phase 1 | none listed |
| ZW171 | Stopped | Phase 1 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Undetermined | 2 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| AbbVie | Route A |
| Roche | Route A |
The other 7 companies at MSLN
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at MSLN, ranked, with the facts behind eachRequest access. Nothing is shown until you do.